|
To determine the effect of adding nateglinide to therapy with insulin glargine
in adults with Type 2 diabetes previously treated with insulin and with poor
blood glucose control. A 16 week-week, double-blind, placebo-controlled study,
with people with Type 2 diabetes for 12 years and an average A1c of 8.2%, duration
of insulin treatment 6.0 +/- 4.0 years] were transferred to single bedtime
injection of insulin glargine for a titration period of 4 weeks, and then randomized
to nateglinide or matching placebo before meals in addition to insulin glargine.
Metformin was continued if taken. Doses of insulin and oral medication were
titrated to protocol for the treatment period of 12 weeks.
The results showed that blood glucose concentration at 12 weeks was significantly
lower with nateglinide + insulin glargine compared with placebo + insulin glargine
after breakfast, before lunch, and after lunch, but not at other times. Baseline-adjusted
HbA(1c) was not lower with nateglinide + insulin glargine as compared with
placebo + insulin glargine.
From the results, Addition of nateglinide before meals to once-daily insulin
glargine in people with long-standing diabetes already requiring insulin therapy
improves blood glucose control in the early part of the day after breakfast
and lunch, but does not provide good control of blood glucose levels overall.
Diabet. Med. Feb 12, 2007
================================
Advertisement
Dr. Philip A. Wood has written a book for healthcare professionals
and students of medicine, nursing, pharmacy, and graduate studies, as well
lay people interested in understanding the influences of genetics, nutrition,
activity level and drugs on diseases associated with excess fat such as obesity,
insulin resistance, metabolic syndrome and type 2 diabetes. The book is composed
of short, readable chapters with helpful figures to further explain the mechanisms
discussed. For further information please click here.
|
Entries (RSS News)
